רווח נקי למניה (EPS TTM): Revance Therapeutics, Inc (RVNC)

The 12-month net income per share history illustrates the dynamics of Revance Therapeutics (RVNC), where -1.94 is the current value of the metric. Revance Therapeutics is resisting aggressive pressure from global aesthetics behemoths. Long-acting neurotoxins ensure stable demand and build customer loyalty. Meanwhile, management is mitigating production outsourcing risks through strict technical control of external sites.
פילוחים אנליטיים ודוחות נתונים של חברת Revance Therapeutics (RVNC)

For Revance Therapeutics (RVNC), which monetizes the premium status of its Daxxify drug, earnings per share serve as the benchmark for the efficiency of capitalizing on its technological advantage. This metric is calculated by dividing the total annual net income by the total number of outstanding shares. The net income per share trend over the last 12 months (TTM) reflects the business's actual ability to generate value. The growth of this indicator confirms the success of its high-pricing strategy. Investors should view this trend as confirmation of the business model's sustainability.